Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers

Journal of Pathology

Volumn 221, Issue 2, 2010, Pages 147-152

  Kim, Min Sung ^a   Hur, Soo Young ^a   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cancer; FOXL2; Granulosa cell tumour; Mutation; Thecoma

Indexed keywords

INHIBIN A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXL2; UNCLASSIFIED DRUG;

ARTICLE; CODON; CONTROLLED STUDY; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEINIZATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEOPLASM; ONCOGENE; OVARY TUMOR; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THECOMA; TUMOR CELL;

ADULT; CHILD; CODON; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENETIC MARKERS; GRANULOSA CELL TUMOR; HUMANS; KOREA; MUTATION, MISSENSE; NEOPLASMS; OVARIAN NEOPLASMS; SEQUENCE ANALYSIS, RNA; THECOMA;

EID: 77952752197     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2688     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Atlas of Tumor Pathology, 3rd Series, No 23. Armed Forces Institute of Pathology: Washington, DC, 1998.
3. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 2004; 15: 122-128. (Pubitemid 38445066)
4. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, et al. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer 1995; 64: 52-59.
5. Coppes MJ, Ye Y, Rackley R, Zhao XL, Liefers GJ, Casey G, et al. Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res 1993; 53: 2712-2714. (Pubitemid 23180501)
6. Jamieson S, Alexiadis M, Fuller PJ. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors. Gynecol Oncol 2004; 95: 603-609. (Pubitemid 39592528)
7. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360: 2719-2729.
8. Cocquet J, Pailhoux E, Jaubert F, Servel N, Xia X, Pannetier M, et al. Evolution and expression of FOXL2. J Med Genet 2002; 39: 916-921.
9. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ ptosis/epicanthus inversus syndrome. Nature Genet 2001; 27: 159-166. (Pubitemid 32157442)
10. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 2004; 131: 933-942. (Pubitemid 38263207)
11. Uda M, Ottolenghi C, Crisponi L, Garcia JE, Deiana M, Kimber W, et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet 2004; 13: 1171-1181. (Pubitemid 38786999)
12. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
13. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006; 12: 57-61. (Pubitemid 43166176)
14. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95 ) gene in non-small cell lung cancer. Oncogene 1999; 18: 3754-3760. (Pubitemid 29338508)
15. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-1480.
16. Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005; 446: 483-488.
17. Lee JW, Soung YH, Park WS, Kim SY, Nam SW, Min WS, et al. BRAF mutations in acute leukemias. Leukemia 2004; 18: 170-172.
18. Lee SH, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias. APMIS 2007; 115: 1357-1363.
19. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25: 1434-1436.
20. Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, et al. Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS 2009; 117: 28-33.
21. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 2002; 29: 4-10. (Pubitemid 34816060)
22. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042. (Pubitemid 32267973)
23. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
24. Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, et al. The specificity of the FOXL2 c.402C > G somatic mutation: a survey of solid tumors. PLoS One 2009; 4: e7988.
25. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202: 336-340. (Pubitemid 38325243)
26. Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 2009; 139: 1130-1142.